RECTIV™ (nitroglycerin (NTG)) Ointment 0.4% is the first and only medication approved by the FDA for the treatment of moderate to severe pain associated with chronic anal fissure (CAF). A small midline tear in the anoderm with associated inflammatory and fibrotic manifestations, chronic anal fissure typically causes pain during and after bowel movements. The pain associated with CAF has been described by patients as “like passing razor blades or broken glass.”

Beginning February 2012, Aptalis Pharma™ has made RECTIV commercially available in the United States. A global specialty pharmaceutical company focused on gastrointestinal diseases and cystic fibrosis, Aptalis Pharma signed an exclusive license agreement with ProStrakan Group plc to market the new ointment in the US.

“I have used nitroglycerin for 10 years to treat my patients but had to get it compounded for them at specialty pharmacies, and generally with health insurance reimbursement issues,” reports Neil Stollman MD, FACP, FACG, AGAF, Chairman, Department of Medicine at Alta Bates Summit Medical Center in Oakland, Calif. and Associate Clinical Professor of Medicine, Division of Gastroenterology at University of California San Francisco. “What is exciting about RECTIV is that now I have a product for which I can write a prescription for my patients who suffer with CAF pain and it is available in pharmacies across America.”

RECTIV was FDA-approved in June 2011 but was not available commercially until now. Topical NTG has been used for many years for CAF, but requires compounding by specialized pharmacies. RECTIV is available for intra-anal use in a standardized, uniform preparation that has been tested in controlled clinical trials.

Clinical Trial Results

In the pivotal Phase 3, three-week, double-blind, placebo-controlled study, patients rated pain intensity using a 100-mm visual analog scale (VAS). Patients with CAF for at least 6 weeks and moderate or severe pain were randomized to receive 0.4% (1.5 mg) nitroglycerin or placebo ointment applied to the anal canal every 12 hours. The adjusted mean change in average pain VAS score from baseline to Days 14-18 was 44 mm for RECTIV and 37 mm for placebo (p=.038; 95% CI: -13.6mm, -0.4 mm).²

The most common adverse events observed in this study for RECTIV and placebo, respectively were headache (64% vs. 41%) and dizziness (5% vs. 0%). Seven of 123 patients (5.7%) in the RECTIV group discontinued treatment due to headache; one of 124 patients (0.8%) in the placebo group discontinued due to headache.²,³
All patients were instructed to take 650 mg of acetaminophen prior to each administration of study medication.1

A physician in private practice in Louisiana who participated in the clinical trial, Dr. Raj Bhandari states: “As with many NTG formulations, headache and dizziness are the most common side effects.” For patients treated with RECTIV, 68% of the headaches were mild, 27% were moderate and 5% were severe. The corresponding figures for placebo were 47%, 46%, and 7%, respectively.3

RECTIV produces dose-related headaches, which may be severe. Tolerance to headache occurs. Headaches may recur after each dose; they are typically short in duration, can be treated with an analgesic, and are reversible upon discontinuation of treatment.2

With regard to dizziness, Dr. Bhandari says he advised patients in the study that the medication could lower their blood pressure, so if they applied the ointment while lying down, they should get up slowly, otherwise they might feel faint.

Hypertonicity of the Internal Anal Sphincter

Othon Wiltz, M.D., F.C.S., F.A.S.C.R.S., head of Washington Colorectal Surgery at Virginia Hospital Center in Arlington, reports that in his practice he sees CAF at Virginia Hospital Center in Arlington, the head of Washington Colorectal Surgery Othon Wiltz, M.D., F..C.S., F.A.S.C.R.S., at Virginia Hospital Center in Arlington, says that in his practice he sees CAF in the posterior anal canal and does not heal. “The pain can be intense, and in the majority of cases does not resolve and are considered chronic when the signs and symptoms persist for more than 8-12 weeks, and there are characteristic features consistent with fibrosis and edema.1

Primary chronic anal fissure is not caused by an underlying chronic disease and is most common in young-to-middle-aged adults. Traditionally, chronic anal fissure was thought to be related to passage of a hard stool; however, recent findings suggest that the pathophysiology of CAF to be hypertonicity of the internal anal sphincter and a breakdown of the anoderm due to decreased blood flow.1

Dr. Stollman states that while patient lifestyle modifications, sitz baths and topical analgesics such as 1% Lidocaine are helpful initial treatments for anal fissures, often these interventions are not sufficient to control pain. About half of all patients with acute anal fissure will respond to conservative measures. The goals of therapy are to relieve the pain and reverse the ischemia which is believed to play a role in the pathophysiology of CAF.4

Nitroglycerin is a vasodilator and causes smooth muscle relaxation of the blood vessel. When applied topically to the anal canal, it increases local blood flow, relaxes anal sphincter tone, and reduces anal pressure. The mechanism of action of RECTIV in association with pain reduction in CAF is unknown. RECTIV is applied twice a day, for up to 3 weeks.2

Important Safety Information

RECTIV is contraindicated in patients taking phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, vardenafil, and tadalaftil), which can potentiate the hypotensive effect of nitrate, and in patients with severe anemia, increased intracranial pressure, or known hypersensitivity to nitroglycerin, other nitrates and nitrites, or any components of the ointment. Patients with certain cardiovascular disorders should be closely monitored while taking RECTIV. Venous and arterial dilation as a consequence of nitroglycerin treatment can result in hypotension. Exercise caution in patients with blood volume depletion, existing hypotension, cardiomyopathies, congestive heart failure, acute myocardial infarction, or poor cardiac function for other reasons. Adverse reactions are likely to be more pronounced in the elderly. A number of drug interactions exist with RECTIV including beta-adrenergic inhibitors, antihypertensives, aspirin, platelet-activator (t-PA), heparin, ergotamine, and alcohol. The most common adverse reactions are headache and dizziness. 

For more information about RECTIV, please call 1-800-950-8085, visit our website at www.aptalispharma.com.

This article was sponsored by Aptalis Pharma US, Inc. RECTIV® and Aptalis Pharma™ are trademarks of Aptalis Pharma US, Inc. or its subsidiaries.

References:
2. RECTIV US Prescribing Information; June 2011
RECTIV (nitroglycerin) Ointment 0.4%, for intra-anal use
Rx Only

Initial U.S. Approval: 1955

Brief summary of Prescribing Information. Please consult package insert for full Prescribing Information.

INDICATIONS AND USAGE: RECTIV™ (nitroglycerin) Ointment 0.4% is indicated for the treatment of angina pectoris associated with chronic anginal pain.

CONTRAINDICATIONS: PDE5 inhibitor use - Administration of RECTIV is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), such as sildenafil, vardenafil, and tadalafil, as these are shown to potentiate the hypotensive effects of organic nitrates (See DRUG INTERACTIONS). Severe anemia - RECTIV is contraindicated in patients with severe anemia. Increased intracranial pressure - RECTIV is contraindicated in patients with increased intracranial pressure. Hypersensitivity - RECTIV is contraindicated in patients who have shown hypersensitivity to it or to other nitrates or nitrites. Skin reactions consistent with hypersensitivity have been observed with organic nitrates.

WARNINGS AND PRECAUTIONS: Cardiovascular disorders - Venous and arterial dilatation as a consequence of nitroglycerin treatment including RECTIV, can decrease venous blood returning to the heart and reduce arterial vascular resistance and systolic pressure. Exercise caution when treating patients with any of the following conditions: blood volume depletion, existing hypotension, cardiomyopathies, congestive heart failure, acute myocardial infarction, or poor cardiac function for other reasons. If patients with any of these conditions are treated with RECTIV, monitor cardiovascular status and clinical condition. The adverse reactions of RECTIV are likely to be more pronounced in the elderly. Headache - RECTIV produces dose-related headaches, which may be severe. Tolerance to headaches occurs.

ADVERSE REACTIONS: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reaction of RECTIV (nitroglycerin) Ointment 0.4% applied to the anal canal is headache. Headache may be recurrent following each dose. Headaches are typically of short duration and can be of short duration and can be treated with an analgesic, e.g., acetaminophen, and are reversible upon discontinuation of treatment. In Study REC-C-001, a double-blind, placebo-controlled trial in patients with a painful chronic anal fissure, the most frequent (≥2%) adverse reactions reported were as follows (Table 1):

Table 1: Incidence of Adverse Reactions (≥2%) in Study REC-C-001

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Preferred term</th>
<th>RECTIV N=123</th>
<th>Placebo N=124</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>79 (64)</td>
<td>938</td>
<td>51 (41)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>6 (5)</td>
<td>26</td>
<td>0</td>
</tr>
</tbody>
</table>

Hypotension: Transient episodes of light-headedness, occasionally related to blood pressure changes, also may occur. Hypotension (including orthostatic hypotension) occurs infrequently, but in some patients may be severe enough to warrant discontinuation of therapy. Allergic Reactions: Flushing, allergic reactions and application site reactions (including drug rash and exfoliative dermatitis) have been reported rarely. Methemoglobinemia, therapeutic doses of organic nitrates have caused methemoglobinemia (see OVERDOSAGE).

DRUG INTERACTIONS: PDE5 inhibitors - Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates. The time course of the interaction appears to be related to the half-life of the PDE5 inhibitor; however, the dose dependence of this interaction has not been studied. Use of RECTIV within a few days of PDE5 inhibitors is contraindicated. Antihypertensives - Patients receiving antihypertensive drugs, beta-adrenergic blockers, and other nitrates should be observed for possible additive hypotensive effects when using RECTIV. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concurrently. Plasma levels of T-PA are reduced when coadministered with nitroglycerin. Therefore, caution should be observed in patients receiving RECTIV during t-PA therapy. Heparin - Although an interaction has been reported between intravenous heparin and intravenous nitroglycerin (resulting in a decrease in the anticoagulant effect of heparin), the data are not consistent. If patients are to receive intravenous heparin and RECTIV concurrently, the anticoagulant status of the patient must be checked. Ergotamine - Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and consequently increases its oral bioavailability. Ergotamine is known to precipitate angina pectoris. Therefore the possibility of ergotism in patients receiving RECTIV should be considered. Alcohol - The vasodilating effects of nitroglycerin have been shown to be additive to those of alcohol observed with alcohol.

USE IN SPECIFIC POPULATIONS: Pregnancy - Pregnancy Category C: Animal reproduction and teratogenicity studies have not been conducted with RECTIV. Nitroglycerin was not teratogenic when administered by topical or dietary route. There are no adequate and well-controlled studies in pregnant women. RECTIV should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Similarly, in xenograft studies in rats and rabbits were conducted with topically applied nitroglycerin ointment at doses up to 80 mg/kg/day and 240 mg/kg/day, respectively. Toxic effects on dams or fetuses were seen at any dose tested. A teratogenicity study was conducted in rats with nitroglycerin administered in the diet at levels up to 1% (approximately 430 mg/kg/day) on days 6 to 15 of gestation. In offspring of the high-dose group, an increased but not statistically significant incidence of diaphragmatic hernias was noted together with decreased hyoid bone ossification. The latter finding probably reflects delayed development; thus indicating no clear evidence of a potential teratogenic effect of nitroglycerin. Nursing Mothers - It is not known whether nitroglycerin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when RECTIV is administered to a nursing woman. Pediatric Use - The safety and effectiveness of RECTIV in pediatric patients under 18 years of age have not been established. Geriatric Use - Clinical studies of RECTIV did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Clinical data from the published literature indicate that the elderly demonstrate increased sensitivity to nitrates, which may be therapeutic but also manifest by more frequent or severe hypotension and related dizziness or fainting. Elderly patients who exhibit such symptoms or signs should be observed. Monitoring of patients with any of these substances can be usefully removed from the body by dialysis. No specific antagonist to the vasodilator effects of nitroglycerin has been developed, and no intervention specific antagonist to the vasodilator effects of nitroglycerin is known, and no such intervention is known. Marked orthostatic hypotension has been reported between intravenous heparin and intravenous nitroglycerin (resulting in a decrease in the anticoagulant effect of heparin), the data are not consistent. If patients are to receive intravenous heparin and RECTIV concurrently, the anticoagulant status of the patient must be checked. Ergotamine - Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and consequently increases its oral bioavailability. Ergotamine is known to precipitate angina pectoris. Therefore the possibility of ergotism in patients receiving RECTIV should be considered. Alcohol - The vasodilating effects of nitroglycerin have been shown to be additive to those of alcohol observed with alcohol.